Try our Advanced Search for more refined results

Review Of Emergent's $325M Smallpox Drug Deal Extended

By Matthew Perlman (June 29, 2022, 8:00 PM EDT) -- Emergent BioSolutions Inc. has given government enforcers additional time to review its planned $325 million deal with Chimerix Inc. for the rights to Tembexa, the first antiviral approved in the U.S. to treat smallpox in all age groups....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!